JP2024533332A - 経口アビラテロン製剤 - Google Patents

経口アビラテロン製剤 Download PDF

Info

Publication number
JP2024533332A
JP2024533332A JP2024515131A JP2024515131A JP2024533332A JP 2024533332 A JP2024533332 A JP 2024533332A JP 2024515131 A JP2024515131 A JP 2024515131A JP 2024515131 A JP2024515131 A JP 2024515131A JP 2024533332 A JP2024533332 A JP 2024533332A
Authority
JP
Japan
Prior art keywords
lipid
abiraterone
drug delivery
delivery system
pharmaceutical composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2024515131A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024533332A5 (https=
Inventor
マシュー， ジェイ． シャープ，
ウィリアム， アール．， ジュニア ムーア，
Original Assignee
プロペラ セラピューティクス インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by プロペラ セラピューティクス インコーポレイテッド filed Critical プロペラ セラピューティクス インコーポレイテッド
Publication of JP2024533332A publication Critical patent/JP2024533332A/ja
Publication of JP2024533332A5 publication Critical patent/JP2024533332A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Dispersion Chemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2024515131A 2021-09-08 2022-09-07 経口アビラテロン製剤 Pending JP2024533332A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202163241705P 2021-09-08 2021-09-08
US63/241,705 2021-09-08
PCT/US2022/042701 WO2023038933A1 (en) 2021-09-08 2022-09-07 Oral abiraterone formulations

Publications (2)

Publication Number Publication Date
JP2024533332A true JP2024533332A (ja) 2024-09-12
JP2024533332A5 JP2024533332A5 (https=) 2025-09-12

Family

ID=83508439

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2024515131A Pending JP2024533332A (ja) 2021-09-08 2022-09-07 経口アビラテロン製剤

Country Status (5)

Country Link
US (1) US20250025417A1 (https=)
EP (1) EP4398873A1 (https=)
JP (1) JP2024533332A (https=)
CN (1) CN118215466A (https=)
WO (1) WO2023038933A1 (https=)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10792292B2 (en) 2019-03-06 2020-10-06 Propella Therapeutics, Inc. Abiraterone prodrugs
CN116490165A (zh) * 2020-09-02 2023-07-25 普洛佩拉治疗公司 阿比特龙前药
US11957696B2 (en) 2021-02-15 2024-04-16 Propella Therapeutics, Inc. Abiraterone prodrugs
CA3243913A1 (en) * 2022-03-01 2023-09-07 Astellas Us Llc Abiraterone prodrugs
WO2024107928A1 (en) * 2022-11-16 2024-05-23 Propella Therapeutics, Inc. Abiraterone decanoate composition and use in therapy

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014009434A1 (en) * 2012-07-11 2014-01-16 Sandoz Ag Self-microemulsifying drug delivery system of abiraterone or abiraterone acetate
WO2014111815A2 (en) * 2013-01-18 2014-07-24 Cortendo Ab (Publ) Abiraterone and analogs thereof for the treatment of diseases associated with cortisol overproduction
WO2020081999A1 (en) 2018-10-18 2020-04-23 Essa Pharma, Inc. Androgen receptor modulators and methods for their use
EP3914234A4 (en) * 2019-01-25 2022-09-14 Shenzhen Pharmacin Co., Ltd. Pharmaceutical compositions
US10792292B2 (en) * 2019-03-06 2020-10-06 Propella Therapeutics, Inc. Abiraterone prodrugs
EP3944860A1 (en) * 2020-07-30 2022-02-02 Galenicum Health S.L.U. Abiraterone for use in a method of treating cancer
CN113929727A (zh) * 2020-09-28 2022-01-14 南京易腾药物研究院有限公司 阿比特龙酯类衍生物及其制备方法和应用
US11957696B2 (en) * 2021-02-15 2024-04-16 Propella Therapeutics, Inc. Abiraterone prodrugs

Also Published As

Publication number Publication date
EP4398873A1 (en) 2024-07-17
WO2023038933A1 (en) 2023-03-16
CN118215466A (zh) 2024-06-18
US20250025417A1 (en) 2025-01-23

Similar Documents

Publication Publication Date Title
US11957696B2 (en) Abiraterone prodrugs
JP2024533332A (ja) 経口アビラテロン製剤
KR102879575B1 (ko) 아비라테론 프로드러그
JP7850366B2 (ja) アビラテロンプロドラッグ
US20250186463A1 (en) Abiraterone decanoate prodrugs and use in therapy
HK40096900A (zh) 阿比特龙前药
RU2822219C2 (ru) Пролекарства абиратерона
HK40130201A (zh) 阿比特龙前药
HK40103488A (en) Abiraterone prodrugs
WO2024107928A1 (en) Abiraterone decanoate composition and use in therapy
HK40120426A (zh) 阿比特龙前药
HK40065545B (zh) 阿比特龙前药

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250904

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20250904

A711 Notification of change in applicant

Free format text: JAPANESE INTERMEDIATE CODE: A712

Effective date: 20260324